Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CCND1 | P24385 | 4/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202125 | 0.87 | P2RX7 (0.53) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL5791630 | 0.87 | P2RX7 (0.53) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL5237341 | 0.84 | HTR2C (0.55) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL14155057 | 0.84 | HTR2C (0.55) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL9994959 | 0.84 | P2RX7 (0.53) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL696591 | 0.83 | P2RX7 (0.52) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL8434667 | 0.82 | HTR2C (0.56) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL5235415 | 0.82 | HTR2C (0.56) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL5635097 | 0.82 | HTR2C (0.53) | P2RX7HTR2CHTR2AHTR7CDK4 | |
| SCHEMBL28833477 | 0.82 | HTR2A (0.53) | P2RX7HTR2CHTR2AHTR7CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1860112-A | 3-amino chroman and 2-amino tetralin derivatives | WYETH CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | P2RX7 1305/4885HTR2C 2/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.